RegulatoryCompany release

CytomX's Varseta-M wins FDA Fast Track in relapsed colorectal cancer; Phase 1 data due January

🇺🇸 CytomX Therapeutics, Inc. (CTMX) · Thu 05 Nov 2026

CytomX Therapeutics reported third-quarter 2026 results alongside news that its EpCAM-directed masked antibody drug conjugate holds Fast Track status, with a registrational study possible in the first half of 2027.

CytomX Therapeutics reported its third-quarter 2026 financial results and a pipeline update on 5 November 2026. The update centred on Varseta-M (varsetatug masetecan), the company's EpCAM-directed masked antibody drug conjugate.

The US Food and Drug Administration granted Varseta-M Fast Track designation in August for relapsed or refractory metastatic colorectal cancer. Fast Track is a programme intended to speed the development and review of therapies for serious conditions with unmet medical need, and it allows more frequent interaction with the agency.

CytomX expects to present an update from its Phase 1 monotherapy study in January 2027. The company said a first registrational study of Varseta-M could begin in the first half of 2027.

On finances, CytomX reported $348.0 million in cash. It said this provides a runway into the second half of 2028.

What it means for your team

  • Regulatory teams tracking colorectal cancer should note that Varseta-M now has Fast Track status, which carries scope for more frequent FDA interaction during development.
  • The January 2027 Phase 1 monotherapy update is the next data point; a registrational study start in 1H 2027 is described as possible, not confirmed.
  • Market-access and competitive-intelligence teams can note the stated cash runway into 2H 2028, which covers the planned move towards a registrational study.

Company's press release (SEC filing): CytomX Therapeutics, Inc. ↗

Article written by VigiEye from the official source (CytomX Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →